Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

Summary

This study is a 4-week, randomized, double-blind, parallel-group, placebo-controlled monotherapy study in patients with treatment-resistant major depression. After confirmation of treatment-resistance in a prospective treatment period with citalopram, each patient will be treated with either EVT 101 once daily or placebo for 28 consecutive days.

Timeline

Start

2010-06

Primary completion

2011-03

Completion

2011-03

Outcome

Outcome not reported

Stopped: “Evotec has indicated that this study was discontinued due to a clinical hold issued by the FDA”

Drugs

Indications